科研成果详情

题名Corrigendum to ' Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders' [Multiple Sclerosis and Related Disorders 58(2022) 103513]
作者
发表日期2022-11
发表期刊Multiple sclerosis and related disorders   影响因子和分区
语种英语
原始文献类型Published Erratum
ISSN2211-0348
EISSN2211-0356
卷号67
DOI10.1016/j.msard.2022.104058
收录类别PUBMED
URL查看原文
PubMed ID36344065
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/185971
专题第一临床医学院(信息与工程学院)、附属第一医院_内科学_神经内科
作者单位
1.Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.;
2.Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address: xiajunhuiwmu@163.com.
第一作者单位第一临床医学院(信息与工程学院)、附属第一医院_内科学_神经内科
第一作者的第一单位第一临床医学院(信息与工程学院)、附属第一医院_内科学_神经内科
推荐引用方式
GB/T 7714
Juyuan Pan,Ruofan Zhu,Jie Lin,et al. Corrigendum to ' Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders' [Multiple Sclerosis and Related Disorders 58(2022) 103513][J]. Multiple sclerosis and related disorders,2022,67.
APA Juyuan Pan, Ruofan Zhu, Jie Lin, Xiang Li, & Junhui Xia. (2022). Corrigendum to ' Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders' [Multiple Sclerosis and Related Disorders 58(2022) 103513]. Multiple sclerosis and related disorders, 67.
MLA Juyuan Pan,et al."Corrigendum to ' Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders' [Multiple Sclerosis and Related Disorders 58(2022) 103513]".Multiple sclerosis and related disorders 67(2022).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Juyuan Pan]的文章
[Ruofan Zhu]的文章
[Jie Lin]的文章
百度学术
百度学术中相似的文章
[Juyuan Pan]的文章
[Ruofan Zhu]的文章
[Jie Lin]的文章
必应学术
必应学术中相似的文章
[Juyuan Pan]的文章
[Ruofan Zhu]的文章
[Jie Lin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。